European Commission approval of Zilbrysq (zilucoplan) for the treatment of adults with generalized myasthenia gravis – UCB
UCB announced that the European Commission (EC) has granted a marketing authorization for Zilbrysq (zilucoplan) as an add-on to standard therapy for the treatment of generalized myasthenia gravis… read more.
